Abstract
The aim of this study was to determine whether the prolactin −1149 G/T polymorphism confers susceptibility to systemic lupus erythematous (SLE) and rheumatoid arthritis (RA). A meta-analysis was conducted for examining the associations between prolactin −1149 G/T polymorphism and susceptibility to SLE or RA using allele contrast, recessive and dominant models, and homozygote contrast. A total of 10 comparative studies, consisting of 4 SLE and 6 RA studies, involving 4252 patients and 4949 controls, were included in the meta-analysis. No association between the prolactin −1149 G allele and SLE was found when all study subjects were considered together (OR = 1.019, 95 % CI = 1.841–1.236, p = 0.845). Stratification by ethnicity also indicated no association between the prolactin G allele and SLE in either Caucasian or Latin American populations. In contrast, a significant association was observed between the prolactin G allele and RA in all subjects (OR = 1.123, 95 % CI = 1.052–1.198, p = 4.6 × 10−5). After stratification by ethnicity, the G allele was found to be significantly associated with RA in Caucasians (OR = 1.112, 95 % CI = 1.041–1.189, p = 0.002). Furthermore, the prolactin −1149 G/T polymorphism was found to be associated with RA in Caucasians under the dominant model and under homozygote contrast. This meta-analysis demonstrates that the prolactin −1149 G/T polymorphism is associated with susceptibility to RA, but not SLE, in Caucasians.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lee YH, Nath SK (2005) Systemic lupus erythematosus susceptibility loci defined by genome scan meta-analysis. Hum Genet 118:434–443
Choi SJ, Rho YH, Ji JD, Song GG, Lee YH (2006) Genome scan meta-analysis of rheumatoid arthritis. Rheumatology 45:166–170
Vera-Lastra O, Jara LJ, Espinoza LR (2002) Prolactin and autoimmunity. Autoimmun Rev 1:360–364
Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB (1990) Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A 87:6460–6464
Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW (1996) Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev 17:639–669
Stevens A, Ray DW, Worthington J, Davis JR (2001) Polymorphisms of the human prolactin gene—implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 10:676–683
Stevens A, Ray D, Alansari A, Hajeer A, Thomson W, Donn R, Ollier WE, Worthington J, Davis JR (2001) Characterization of a prolactin gene polymorphism and its associations with systemic lupus erythematosus. Arthritis Rheum 44:2358–2366
Fojtikova M, Cerna M, Cejkova P, Ruzickova S, Dostal C (2007) Extrapituitary prolactin promoter polymorphism in Czech patients with systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis 66:706–707
Reyes-Castillo Z, Pereira-Suarez AL, Palafox-Sanchez CA, Rangel-Villalobos H, Estrada-Chavez C, Oregon-Romero E, Angel-Chavez LI, Munoz-Barrios S, Bueno-Topete MR, Munoz-Valle JF (2013) The extrapituitary prolactin promoter polymorphism is associated with rheumatoid arthritis and anti-CCP antibodies in Mexican population. Gene 525:130–135
Montoya-Diaz E, Cervera-Castillo H, Chavez-Sanchez L, Legorreta-Haquet MV, Sanchez-Gonzalez L, Chavez-Rueda K, Blanco-Favela F (2011) Prolactin promoter polymorphism (−1149 G/T) is associated with anti-DNA antibodies in Mexican patients with systemic lupus erythematosus. Immunol Investig 40:614–626
Mellai M, Giordano M, D’Alfonso S, Marchini M, Scorza R, Giovanna Danieli M, Leone M, Ferro I, Liguori M, Trojano M, Ballerini C, Massacesi L, Cannoni S, Bomprezzi R, Momigliano-Richiardi P (2003) Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Hum Immunol 64:274–284
Lee YC, Raychaudhuri S, Cui J, De Vivo I, Ding B, Alfredsson L, Padyukov L, Costenbader KH, Seielstad M, Graham RR, Klareskog L, Gregersen PK, Plenge RM, Karlson EW (2009) The PRL −1149 G/T polymorphism and rheumatoid arthritis susceptibility. Arthritis Rheum 60:1250–1254
Lee YH, Harley JB, Nath SK (2006) Meta-analysis of TNF-alpha promoter −308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet: EJHG 14:364–371
Nath SK, Harley JB, Lee YH (2005) Polymorphisms of complement receptor 1 and interleukin-10 genes and systemic lupus erythematosus: a meta-analysis. Hum Genet 118:225–234
Lee YH, Rho YH, Choi SJ, Ji JD, Song GG (2006) Association of TNF-alpha −308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheumatol Int 27:157–161
Davey Smith G, Egger M (1997) Meta-analyses of randomised controlled trials. Lancet 350:1182
Egger M, Smith GD, Phillips AN (1997) Meta-analysis: principles and procedures. BMJ 315:1533–1537
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558
Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634
Peeva E, Gonzalez J, Hicks R, Diamond B (2006) Cutting edge: lupus susceptibility interval Sle3/5 confers responsiveness to prolactin in C57BL/6 mice. J Immunol 177:1401–1405
Mohan C, Yu Y, Morel L, Yang P, Wakeland EK (1999) Genetic dissection of Sle pathogenesis: Sle3 on murine chromosome 7 impacts T cell activation, differentiation, and cell death. J Immunol 162:6492–6502
Acknowledgments
This study was supported in part by a grant of the Korea Healthcare technology R&D Project, Ministry for Health and Welfare, Republic of Korea (HI13C2124).
Conflict of interest
The authors have no conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, Y.H., Bae, SC. & Song, G.G. Meta-analysis of associations between functional prolactin −1149 G/T polymorphism and susceptibility to rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol 34, 683–690 (2015). https://doi.org/10.1007/s10067-015-2904-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-015-2904-3